These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7508010)

  • 21. Structure-activity relationships for the hypertensinogenic activity of ouabain: role of the sugar and lactone ring.
    Manunta P; Hamilton BP; Hamlyn JM
    Hypertension; 2001 Feb; 37(2 Pt 2):472-7. PubMed ID: 11230321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure.
    Manunta P; Rogowski AC; Hamilton BP; Hamlyn JM
    J Hypertens; 1994 May; 12(5):549-60. PubMed ID: 7930555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate.
    Tao QF; Hollenberg NK; Price DA; Graves SW
    Hypertension; 1997 Mar; 29(3):815-21. PubMed ID: 9052901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma potassium may protect sodium pumps of toad hearts from an endogenous inhibitor.
    Else PL
    Am J Physiol; 1994 Sep; 267(3 Pt 2):R754-61. PubMed ID: 8092319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potassium, Na+-K+ pump inhibitor and low-renin hypertension.
    Haddy FJ
    Clin Invest Med; 1987 Nov; 10(6):547-54. PubMed ID: 2831002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertensive effects of the iv administration of picomoles of ouabain.
    Padilha AS; Salaices M; Vassallo DV; Batista PR; Siman FD
    Braz J Med Biol Res; 2011 Sep; 44(9):933-8. PubMed ID: 21956536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypotensive action of canrenone in a model of hypertension where ouabain-like factors are present.
    De Mendonca M; Grichois ML; Pernollet MG; Thorman B; Meyer P; Devynck MA; Garay R
    J Hypertens Suppl; 1985 Dec; 3(3):S73-5. PubMed ID: 2856827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.
    Ferrari P; Ferrandi M; Tripodi G; Torielli L; Padoani G; Minotti E; Melloni P; Bianchi G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1074-83. PubMed ID: 10027844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma marinobufagenin-like and ouabain-like immunoreactivity in adrenocorticotropin-treated rats.
    Fedorova OV; Anderson DE; Bagrov AY
    Am J Hypertens; 1998 Jul; 11(7):796-802. PubMed ID: 9683040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of Na,K-ATPase inhibitor on pressor responsiveness in patients with benign essential hypertension.
    Yamaji I; Kikuchi K; Nishimura M; Nozawa A; Hasegawa T; Kobayakawa H; Komura H; Iimura O
    Am J Hypertens; 1990 Mar; 3(3):176-81. PubMed ID: 2157465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Na⁺, K⁺-ATPase activity and endothelial modulation decrease phenylephrine-induced contraction in aorta from ouabain-treated normotensive and hypertensive rats.
    Davel AP; Couto GK; Wenceslau CF; Peres EC; Xavier FE; Rossoni LV
    Horm Mol Biol Clin Investig; 2014 May; 18(2):113-22. PubMed ID: 25390007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain Na+,K+-ATPase isozyme activity and protein expression in ouabain-induced hypertension.
    Kent MA; Huang BS; Van Huysse JW; Leenen FH
    Brain Res; 2004 Aug; 1018(2):171-80. PubMed ID: 15276875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor.
    Fedorova OV; Zhuravin IA; Agalakova NI; Yamova LA; Talan MI; Lakatta EG; Bagrov AY
    J Hypertens; 2007 Sep; 25(9):1834-44. PubMed ID: 17762648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral sodium transport inhibitor in acute volume expansion and low renin hypertension.
    Pamnani MB; Bryant HJ; Haddy FJ
    Hypertension; 1987 Nov; 10(5 Pt 2):I78-83. PubMed ID: 2824371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Na-K-ATPase inhibitor dissociated from hypertension-associated plasma protein.
    Weiler EW; Khalil-Manesh F; Gonick HC; Prins BA; Purdy RE; Sensharma DK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):364-73. PubMed ID: 10232496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma endogenous sodium pump inhibitor in essential hypertension.
    Cloix JF; Devynck MA; Elghozi JL; Kamal LA; Lacerda-Jacomini LC; Meyer P; Pernollet MG; Rosenfeld JB; De Thé H
    J Hypertens Suppl; 1983 Dec; 1(2):11-4. PubMed ID: 6100615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats.
    Fedorova OV; Lakatta EG; Bagrov AY
    Circulation; 2000 Dec; 102(24):3009-14. PubMed ID: 11113054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-dependent effect of ouabain on renal Na+,K+-ATPase.
    Silva E; Serrão MP; Soares-da-Silva P
    Life Sci; 2011 Apr; 88(15-16):719-24. PubMed ID: 21338612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of ouabain on pressor responses to infused noradrenaline in patients with essential hypertension.
    Nishimura M; Kikuchi K; Aoki K; Nozawa A; Honma C; Kobayakawa H; Yamamoto M; Shimazaki M; Kudoh C; Sakamoto T
    J Hypertens Suppl; 1988 Dec; 6(4):S354-6. PubMed ID: 2853744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypothalamic Na+,K(+)-ATPase inhibitor constricts pulmonary arteries of spontaneously hypertensive rats.
    Janssens SP; Kachoris C; Parker WL; Hales CA; Haupert GT
    J Cardiovasc Pharmacol; 1993; 22 Suppl 2():S42-6. PubMed ID: 7508026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.